Analyzing tumors better and faster
11.02.2016
Personalized medicine is a growing trend in cancer medicine. And it is not without reason either: therapies tailored to patient requirements promise to be more effective and work more rapidly. For this to become a reality, the industry requires technologies that enable diagnoses to be made quick, simple and for a reasonable price.
 The competitive skills of the Lunaphore team range from micromechanics to bioengineering.
|
 |
The 2015 Venture Kick winner Lunaphore is currently developing an innovation of this kind. Their „fast fluidic exchange „technology allows the rapid and accurate profiling of biomarkers in cancerous tissues. This brings a significant improvement to the current tissue coloration assays that make the analysis and the detection of cancerous tumors possible.
The solution developed by Lunaphore is ten to twenty times faster than current assays and more accurate: up to 90 % compared to existing technologies. And the market is huge: a few tens of millions of tests are performed every year worldwide with a volume close to USD 2 billion for routine diagnostic tests alone. In the long term, Lunaphore’s vision is to build a standardized and fully automated tumor analysis platform for all cancer biomarkers. The EPFL spin-off’s primary markets will be Germany - the largest medtech market in Europe - and the U.S. In 2014, Lunaphore’s CEO had joined the venture leaders USA team to discover the market’s potential for his venture.
A competitive team to build a first product
Lunaphore’s team headed by Ata Tuna Ciftlik, Deborah Heintze and Diego Dupouy could count on the support of Venture Kick from the beginning: „The program helped us increase our credibility and visibility in the Swiss startup scene. Thanks to the kickers camps, we could tackle against all the odds that might have killed our project at every stage of its development“.
In 2015, Lunaphore convinced investors of their worth and completed a financing round to the tune of CHF 2 million. With the funds, Lunaphore has started to work towards their first product as well as building a competitive team of 12 people in 2015. The company has also moved into newer and bigger offices at the EPFL Innovation Park. Lunaphore won additional recognition in 2015 as it was elected as 2nd best Swiss medtech start-up after Abionic by the TOP100 Swiss Startups award (on rank No. 10). In March 2015, the company was among the ten winners of the Science4Life competition in Berlin.
The solution developed by Lunaphore is ten to twenty times faster than current assays and more accurate: up to 90 % compared to existing technologies. And the market is huge: a few tens of millions of tests are performed every year worldwide with a volume close to USD 2 billion for routine diagnostic tests alone. In the long term, Lunaphore’s vision is to build a standardized and fully automated tumor analysis platform for all cancer biomarkers. The EPFL spin-off’s primary markets will be Germany - the largest medtech market in Europe - and the U.S. In 2014, Lunaphore’s CEO had joined the venture leaders USA team to discover the market’s potential for his venture.
A competitive team to build a first product
Lunaphore’s team headed by Ata Tuna Ciftlik, Deborah Heintze and Diego Dupouy could count on the support of Venture Kick from the beginning: „The program helped us increase our credibility and visibility in the Swiss startup scene. Thanks to the kickers camps, we could tackle against all the odds that might have killed our project at every stage of its development“.
In 2015, Lunaphore convinced investors of their worth and completed a financing round to the tune of CHF 2 million. With the funds, Lunaphore has started to work towards their first product as well as building a competitive team of 12 people in 2015. The company has also moved into newer and bigger offices at the EPFL Innovation Park. Lunaphore won additional recognition in 2015 as it was elected as 2nd best Swiss medtech start-up after Abionic by the TOP100 Swiss Startups award (on rank No. 10). In March 2015, the company was among the ten winners of the Science4Life competition in Berlin.